These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36039688)

  • 1. Prognostic value of soluble urokinase-type plasminogen activator receptor in coronary artery disease: A meta-analysis.
    Li Y; Ding Y; Zhao Y; Gui Y; Shen Y; Xiang Q
    Eur J Clin Invest; 2022 Dec; 52(12):e13867. PubMed ID: 36039688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardio-Renal Biomarker Soluble Urokinase-Type Plasminogen Activator Receptor Is Associated With Cardiovascular Death and Myocardial Infarction in Patients With Coronary Artery Disease Independent of Troponin, C-Reactive Protein, and Renal Function.
    Nikorowitsch J; Borchardt T; Appelbaum S; Ojeda F; Lackner KJ; Schnabel RB; Blankenberg S; Zeller T; Karakas M
    J Am Heart Assoc; 2020 Apr; 9(8):e015452. PubMed ID: 32299288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble urokinase Plasminogen Activator Receptor (suPAR) mediates the effect of a lower education level on adverse outcomes in patients with coronary artery disease.
    Füller D; Liu C; Ko YA; Alkhoder AA; Desai SR; Almuwaqqat Z; Patel SA; Ejaz K; Kauser T; Martini MA; Alvi Z; Mehta PK; Sperling LS; Quyyumi AA
    Eur J Prev Cardiol; 2024 Mar; 31(5):521-528. PubMed ID: 37788634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble Urokinase-Type Plasminogen Activator Receptor and High-Sensitivity Troponin Levels Predict Outcomes in Nonobstructive Coronary Artery Disease.
    Al-Badri A; Tahhan AS; Sabbak N; Alkhoder A; Liu C; Ko YA; Vaccarino V; Martini A; Sidoti A; Goodwin C; Ghazzal B; Beshiri A; Murtagh G; Mehta PK; Quyyumi AA
    J Am Heart Assoc; 2020 Apr; 9(8):e015515. PubMed ID: 32301366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble urokinase plasminogen activator receptor level is an independent predictor of the presence and severity of coronary artery disease and of future adverse events.
    Eapen DJ; Manocha P; Ghasemzadeh N; Patel RS; Al Kassem H; Hammadah M; Veledar E; Le NA; Pielak T; Thorball CW; Velegraki A; Kremastinos DT; Lerakis S; Sperling L; Quyyumi AA
    J Am Heart Assoc; 2014 Oct; 3(5):e001118. PubMed ID: 25341887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting Mortality in African Americans With Type 2 Diabetes Mellitus: Soluble Urokinase Plasminogen Activator Receptor, Coronary Artery Calcium, and High-Sensitivity C-Reactive Protein.
    Hayek SS; Divers J; Raad M; Xu J; Bowden DW; Tracy M; Reiser J; Freedman BI
    J Am Heart Assoc; 2018 May; 7(9):. PubMed ID: 29716888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble urokinase plasminogen activator receptor as a long-term prognostic biomarker in acute coronary syndromes.
    Peiró ÓM; Cediel G; Bonet G; Rojas S; Quintern V; Carrasquer A; González-Del-Hoyo M; Sanz E; Bardají A
    Biomarkers; 2020 Jul; 25(5):402-409. PubMed ID: 32551985
    [No Abstract]   [Full Text] [Related]  

  • 8. Soluble urokinase plasminogen activator receptor and functionally relevant coronary artery disease: a prospective cohort study.
    Walter JE; Amrein MLF; Schäfer I; Zimmermann T; Lopez-Ayala P; Boeddinghaus J; Twerenbold R; Puelacher C; Nestelberger T; Wussler D; Honegger U; Badertscher P; Eugen-Olsen J; Koechlin L; Fahrni G; Jeger R; Kaiser C; Zellweger M; Mueller C
    Biomarkers; 2022 May; 27(3):278-285. PubMed ID: 35112976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SuPAR is associated with death and adverse cardiovascular outcomes in patients with suspected coronary artery disease.
    Hodges G; Lyngbæk S; Selmer C; Ahlehoff O; Theilade S; Sehestedt TB; Abildgaard U; Eugen-Olsen J; Galløe AM; Hansen PR; Jeppesen JL; Bang CN
    Scand Cardiovasc J; 2020 Dec; 54(6):339-345. PubMed ID: 32400206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sex Differences in Circulating Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels and Adverse Outcomes in Coronary Artery Disease.
    Mehta A; Desai SR; Ko YA; Liu C; Dhindsa DS; Nayak A; Hooda A; Martini MA; Ejaz K; Sperling LS; Reiser J; Hayek SS; Quyyumi AA
    J Am Heart Assoc; 2020 Mar; 9(5):e015457. PubMed ID: 32089048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes.
    Samman Tahhan A; Hayek SS; Sandesara P; Hajjari J; Hammadah M; O'Neal WT; Kelli HM; Alkhoder A; Ghasemzadeh N; Ko YA; Aida H; Gafeer MM; Abdelhadi N; Mohammed KH; Patel K; Arya S; Reiser J; Vaccarino V; Sperling L; Quyyumi A
    Atherosclerosis; 2017 Sep; 264():108-114. PubMed ID: 28728756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes.
    Rotbain Curovic V; Theilade S; Winther SA; Tofte N; Eugen-Olsen J; Persson F; Hansen TW; Jeppesen J; Rossing P
    Diabetes Care; 2019 Jun; 42(6):1112-1119. PubMed ID: 30885954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble urokinase plasminogen activator receptor: a risk factor for carotid plaque, stroke, and coronary artery disease.
    Persson M; Östling G; Smith G; Hamrefors V; Melander O; Hedblad B; Engström G
    Stroke; 2014 Jan; 45(1):18-23. PubMed ID: 24253546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble Urokinase-Type Plasminogen Activator Receptor Improves Risk Prediction in Patients With Chronic Heart Failure.
    Koller L; Stojkovic S; Richter B; Sulzgruber P; Potolidis C; Liebhart F; Mörtl D; Berger R; Goliasch G; Wojta J; Hülsmann M; Niessner A
    JACC Heart Fail; 2017 Apr; 5(4):268-277. PubMed ID: 28359415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble urokinase plasminogen activator receptor (suPAR) as a prognostic marker of mortality in healthy, general and patient populations: protocol for a systematic review and meta-analysis.
    Petersen JEV; Kallemose T; Barton KD; Caspi A; Rasmussen LJH
    BMJ Open; 2020 Jul; 10(7):e036125. PubMed ID: 32690515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of soluble urokinase plasminogen activator receptor to predict repeat myocardial infarction and mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention.
    Lyngbæk S; Marott JL; Møller DV; Christiansen M; Iversen KK; Clemmensen PM; Eugen-Olsen J; Jeppesen JL; Hansen PR
    Am J Cardiol; 2012 Dec; 110(12):1756-63. PubMed ID: 22981263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Activation Mediates the Association of Advanced Hepatic Fibrosis With Adverse Outcomes in Patients With Coronary Artery Disease.
    Jain V; Mehta A; Lee TB; Liu C; Chew NWS; Ko YA; Gold ME; Gold DA; Vatsa N; Desai SR; Kim JH; Rahbar A; Haroun Y; Ejaz K; Hayek SS; Siddiqui MS; Salloum FN; Sperling LS; Sanyal AJ; Quyyumi AA
    J Am Heart Assoc; 2023 Dec; 12(24):e031230. PubMed ID: 38063161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between Soluble Urokinase-Type Plasminogen Activator Receptor Levels and Chronic Kidney Disease: A Systematic Review and Meta-Analysis.
    Shuai T; Yan P; Xiong H; Huang Q; Zhu L; Yang K; Liu J
    Biomed Res Int; 2019; 2019():6927456. PubMed ID: 31886242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of soluble urokinase-type plasminogen activator receptor for mortality in patients with suspected myocardial infarction.
    Sörensen NA; Nikorowitsch J; Neumann JT; Rübsamen N; Goßling A; Hartikainen TS; Blankenberg S; Westermann D; Zeller T; Karakas M
    Clin Res Cardiol; 2019 Dec; 108(12):1386-1393. PubMed ID: 30989318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathway-Specific Aggregate Biomarker Risk Score Is Associated With Burden of Coronary Artery Disease and Predicts Near-Term Risk of Myocardial Infarction and Death.
    Ghasemzedah N; Hayek SS; Ko YA; Eapen DJ; Patel RS; Manocha P; Al Kassem H; Khayata M; Veledar E; Kremastinos D; Thorball CW; Pielak T; Sikora S; Zafari AM; Lerakis S; Sperling L; Vaccarino V; Epstein SE; Quyyumi AA
    Circ Cardiovasc Qual Outcomes; 2017 Mar; 10(3):. PubMed ID: 28280039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.